Terry Opgenorth, Ph.D., serves as VP and Executive Director of LAUNCHPAD for CSU Ventures. Dr. Opgenorth previously worked for Abbott Laboratories’ (now AbbVie) as Vice President of Metabolic Disease, Antiviral and Target-Lead Discovery Research for its Global Pharmaceutical Research and Development Division. He also served as President and CEO of Vidasym for 6 years, creating partnerships with companies in Japan and China to advance two drugs into clinical development for human chronic kidney disease. Terry holds a number of other positions, including CSO/Founder of VetDC, a veterinary oncology company, and Board Director KromaTiD, VetDC, UNeMed, MonImmune Therapeutics, Cetya Therapeutics, and PhotonPharma. He previously served as Founder/Advisor to Colorado Center for Drug Discovery (C2D2), and Board Director for Colorado Institute for Drug, Device, and Diagnostic Development (CID4), Colorado Bioscience Association, and Keystone Symposia. Dr. Opgenorth holds a B.A. in Biology from Calvin College and M.S. and Ph.D. degrees in Physiology from University of Illinois-Urbana.